On behalf of the Board of Directors, it is a pleasure to present the 21st Annual Report of the Company along with the auditedFinancial Statements (both standalone and consolidated) and Auditors' Report for the financial year ended March 31, 2025('2024-25'). This is the first annual report after the Initial Public Offering (“IPO") of the Company. The Board appreciates and isthankful for the continued support of all the shareholders throughout the journey of the Company from incorporated as privatelimited company conversion into public limited company and now as a listed company.
Financial highlights of the Company for 2024-25 as compared to the preceding 2023-24, on standalone and consolidated basisare summarized below:
(INR in Million)
Particulars
Standalone
Consolidated
2024-25
2023-24
Revenue from operations
1,712.44
1,393.88
2391.07
1935.55
Other income
46.20
52.94
33.38
17.09
Total income
1,758.64
1,446.82
2,424.45
1952.64
Profit/(Loss) before Depreciation, Finance Costs, Tax andExceptional item
307.94
165.61
452.11
254.99
Less: Depreciation and amortization expenses
98.17
91.21
150.19
119.36
Less: Finance Costs
36.50
42.17
53.90
49.54
Add: Exceptional items
70.27
-
(0.85)
Profit / (Loss) before Tax
243.54
32.23
318.29
85.24
Less: Tax Expenses
57.47
(104.20)
64.54
(94.17)
Add : Share in Profit after Tax of Joint Ventures
71.68
90.67
88.88
Profit / (Loss) After Tax for the year from continuing operations
257.75
227.10
325.43
268.29
Add: Loss Before Tax from Discontinuing Operations
(8.09)
(16.00)
Add: Tax income from Discontinuing Operations
1.00
Profit / (Loss) for the year
318.34
252.29
Add: Other comprehensive Income/ (Loss) for the year
(5.48)
3.85
(5.34)
(1.40)
Total comprehensive Income / (Loss) for the year
252.27
230.95
313.00
250.89
(The Name of the Company has been changed from Laxmi Dental Export Private Limited to Laxmi Dental Private Limited,further, consequent upon conversion to Public Company the name of the Company has been changed from Laxmi DentalPrivate Limited to Laxmi Dental Limited with effect from August 02, 2024 CIN: L51507MH2004PLC147394).
During the financial year, the Company on a standalone basis has reported a total income of INR 1,758.64 Million againstINR 1,446.82 Million in the previous financial year. The profit (after tax) stood at INR 257.75 Million against INR 227.10Million in the previous financial year
During the financial year the Company on a consolidated basis has reported total income of INR 2,424.45 Million againstINR 1,952.64 Million in the previous financial year. The profit (after tax) stood at INR 318.34 Million against INR 252.29Million in the previous financial year
We Laxmi Dental Limited (Formerly Known as "Laxmi DentalExport Private Limited") have a brand presence of more than21 years and we are amongst the top two largest dentallaboratories in India based on revenue for the Fiscal 2025.We are a vertically integrated and B2B2C dental alignercompany, and the largest and most profitable indigenousdental aligner company in terms of revenue from operationsand Profit after Tax ("PAT") Margin respectively as of March31, 2025. We manufacture our dental products across our sixmanufacturing facilities and five supporting facilities spreadacross more than 1,47,029.63 square feet as of March 31,2025.
Our laboratory has an extensive brand presence of morethan 21 years in the dental laboratories business andhas evolved from a two-member dental laboratory to anintegrated dental products company. We are amongst thetop two largest dental laboratories in India by revenue forFiscal 2025 catering to domestic markets and internationalmarkets including USA, UK and Europe. Among the Indiandental labs, we are the largest exporter in terms of exportvalue as of 604.9 Million, for custom made dental prosthesis,catering primarily to US and UK. We are the preferredpartner for one of the largest D50 in the USA with more than1,650 clinics in the USA. Having evolved from a two-memberdental laboratory to an integrated dental products companywe now have a legacy of 21 years in the dental laboratoriesbusiness with a reach of over more than 20,000 dentalclinics, dental companies and dentists between Fiscals 2022to 2025 ("Dental Network").
In terms of retail sales, the Indian market for custom-made crowns and bridges is estimated to grow from US$1.4 Billion in 2023 to US$ 3.1 Billion in 2030 at a higherrate of 11.8% compared to the global market which isestimated to grow from US$ 71 Billion in 2023 to US$121.6 Billion in 2030 at a rate of 8.0%. The Indian dentallaboratories market is characterized by the presence offragmented and unorganized dental laboratories with lessthan ten technicians and a dearth of quality managementstandard compliant dental products. Changing regulatoryrequirements in the medical devices sector is expected totransition the fragmented and unorganized dental productsand consumables market to organized and consolidatedmarket dominated by companies focusing on quality,operational efficiency, and consumer experience.
During the financial year, there was no change in the natureof business of the Company and the Company continues tofocus on improving its operational efficiencies.
In order to conserve the resources of the Company, yourdirectors do not recommend any dividend for the financialyear ended on March 31, 2025.
The Company is not required to transfer any amount ofunpaid/unclaimed dividend or any other amount to theInvestor Education and Protection Fund during the financialyear under review.
The Company has not transferred any amount to the generalreserves or any other reserve for the financial year underreview.
As on March 31, 2025, the Authorized Share Capital ofthe Company is INR 25,00,00,000 (Rupees Twenty-FiveCrores Only) consisting of:
1. 6,50,00,000 (Six Crore Fifty Lacs) Equity Sharesof face value of INR 2/- (Indian Rupees Two) eachand;
2. 3,00,000 (Three Lacs) Preference Shares of facevalue of INR 400/- (Indian Rupees Four Hundred)each.
During the financial year under review, followingchange occurred in the Authorized Share Capital of theCompany:
> On June 07, 2024, the Authorized Share Capitalof the Company has been increased from INR
14.46.00. 000 (Indian Rupees Fourteen CroresForty-Six Lacs) consisting of 24,60,000 (TwentyFour Lacs Sixty Thousand) Equity Shares of facevalue of INR 10/- (Indian Rupees Ten) each and
3.00. 000 (Three Lacs) Preference Shares of facevalue of INR 400/- (Indian Rupees Four Hundred)each to INR 25,00,00,000 (Indian Rupees Twenty-Five Crores Only) consisting of 1,30,00,000 (OneCrore Thirty Lacs) Equity Shares of face value ofI N R 1 0/- (I ndia n Ru pees Ten) each and 3, 00, 000(Three Lacs) Preference Shares of face value ofINR 400/- (Indian Rupees Four Hundred) each.
> In accordance with the provisions of Section 61(1)(d) of the Companies Act, 2013 ("the Act"), theshareholders passed a resolution in its Extra
Ordinary General meeting (“EGM”) held on June07, 2024, approving the sub-division of the EquityShares of the Company thereby reducing the facevalue of each Equity Share having face value ofINR 10/- (Indian Rupees Ten) each fully paid up in¬to face value of INR 2 (Indian Rupees Two) eachfully paid up.
As on March 31, 2025, the Paid-Up Share Capital ofthe Company is INR 10,99,24,298 (Indian Rupees TenCrores Ninety-Nine Lacs Twenty-Four Thousand TwoHundred Ninety-Eight Only) consisting of 54,962,149Equity Shares of face value of INR 2/- (Indian RupeesTwo) each.
During the financial year, following changes haveoccurred in the Paid-up Share Capital of the Company:
A. Private Placement: On May 30, 2024, in accordancewith Section 42 of the Act, the shareholders' inits EGM had approved issuance of 1,146 EquityShares of face value of INR 10/- (Indian RupeesTen) each at a price of INR 13,092 (Indian RupeesThirteen Thousand and Ninety-Two Only includingpremium of INR 13,082) for consideration otherthan cash, pursuant to a Share Swap Agreementdated May 31, 2024 entered into between BizdentDevices Private Limited, Mr. Anil Tilakraj Arora,Mrs. Jyotika Anil Arora and your Company.Further, the Board of Directors in its meeting heldon June 04, 2024 has approved allotment of 1,146Equity Shares.
Pursuant to the said allotment, the issued,subscribed and paid-up Equity Shares and paid-up equity share capital of the Company increasedfrom INR 30,79,140/- (Indian Rupees Thirty LacsSeventy-Nine Thousand One Hundred Forty)divided into 3,07,914 Equity Shares of face valueof INR 10/- (Indian Rupees Ten) each to INR30,90,600/- (Indian Rupees Thirty Lacs NinetyThousand Six Hundred) divided into 3,09,060Equity Shares of face value of INR 10/- (IndianRupees Ten) each.
B. Sub-division of Equity Share: On June 07, 2024,in accordance with Section 61(1)(d) of the Act, theshareholders of the Company had approved thesub-division of the Equity Shares of the Companythereby reducing the face value of each EquityShare.
Pursuant to the sub-division, the issued,subscribed and paid-up Equity Shares i.e. 3,09,060Equity Shares having face value of INR 10/- (IndianRupees Ten) each, stood the sub-divided into15,45,300 Equity Shares having face value of INR2/- (Indian Rupees Two) each without altering theaggregate amount of such capital.
On June 07, 2024 shareholders' in its EGMhad approved the issuance of bonus shares,in proportion of 1 Equity Share (having a facevalue of INR 2/- each) for every 17 Equity Sharesheld by an equity shareholder of the Company,and subsequently the Board of Director of theCompany in its meeting held on June 14, 2024allotted 2,62,70,100 Equity Share (having a facevalue of INR 2/- each) in accordance with Section63 of the Act.
Pursuant to the bonus issuance, the issued,subscribed and paid-up equity share capital of theCompany increased from INR 30,90,600/- (IndianRupees Thirty Lacs Ninety Thousand Six Hundred)divided into 15,45,300 Equity Shares of facevalue of INR 2/- (Indian Rupees Two) each to INR5,56,30,800/- (Indian Rupees Five Crores Fifty-SixLacs Thirty Thousand Eight Hundred) divided into2,78,15,400 Equity Shares of face value of INR 2/-(Indian Rupees Two) each.
On December 19, 2024, the Company hadconverted 2,90,597 outstanding Series A CCPSinto 2,39,22,450 Equity Shares. The conversion ofsuch CCPS into Equity Shares was on a ratio of 1CCPS into 82.3217377 Equity Shares of face valueINR 2/- each.
Pursuant to conversion of the CCPS into EquityShares, the issued equity share capital of theCompany increased from INR 5,56,30,800/-divided into 2,78,15,400 Equity Shares of facevalue of INR 2/- each to INR 10,34,75,700/- dividedinto 5,17,37,850 Equity Shares of face value of INR2/- each and the issued, subscribed and paid-up preference share capital of the Company wasreduced to Nil.
During 2024-25, the Company had issued andallotted 32,24,299 Equity Shares of INR 2/- each,at an issue price of INR 428.00 per fully paid-upequity share (including a premium of INR 426per equity share) pursuant to Initial Public Offeras approved by the Board of Directors in theirmeeting held on January 16, 2025.
The funds received pursuant to Public Issue,have been utilized for the objects stated in theprospectus.
During the period under review, your Companyhad successfully completed its Initial PublicOffer (“IPO") of 1,63,09,766 Equity Shares of facevalue INR 2/- each for cash at a price of INR 428
including a share premium of INR 426 per equityshare, aggregating up-to INR 6,98,05,80,000/-.The offer comprises:
a. Fresh Issue of 32,24,299 equity shares of facevalue of INR 2 each at a price of INR 428 perequity share including a share premium ofINR 426 per equity share aggregating to INR1,37,99,99,972/- and
b. An offer for sale of 1,30,85,467 equity sharesof face value of INR 2 each at a price of INR 428per equity share including a share premiumof INR 426 per equity share aggregating toINR 5,60,05,79,876/-.
The Company successfully completed the IPOprocess, and Equity Shares of the Company werelisted on BSE Limited (“BSE") and National StockExchange of India Limited (“NSE") on January 20,2025.
The Company has 5 (Five) subsidiaries including foreign subsidiary, 2 (Two) Step Down Subsidiary, 1 (One) Joint Venture and 1(One) Associate Company as on March 31, 2025:
Sl.
No.
Name of the Companies/LLP
Percentage of holding
Type
1
Laxmi Dental Lab USA INC
100.00
Subsidiary
2
Bizdent Devices Private Limited
Wholly Owned Subsidiary
3
Signature Smiles Dental Clinic Private Limited
4
Rich Smile Design LLP
66.00
5
Kids-e-Dental LLP
60.00
Joint Venture
6
1Diverse Dental Lab LLC
Step-Down Subsidiary
7
2Illusion Dental Lab USA INC
8
ECGPLUS Technologies Private Limited
41.70
Associate
'Subsidiary of Laxmi Dental Lab USA INC.
"Illusion Dental Lab USA INC, Wholly Owned Material Subsidiary of Laxmi Dental Lab USA INC.
During the financial year 2024-25, Bizdent Devices Private Limited and Laxmi Dental Lab USA INC were material subsidiarypursuant to Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI ListingRegulations").
The Board reviewed the affairs of the subsidiaries and found that there has been no material change in the nature of thebusiness of such subsidiaries.
The Company has formulated a policy for determining material subsidiaries. The policy is available on the website of theCompany at: https://www.laxmidentallimited.com/public/investors/policies/Determination-of-Material-Subsidiaries.pdf.
Further, no Company has become or ceased to be a subsidiary, joint venture or associate company of the Company during2024-25.
Pursuant to Section 129(3) of the Act, a statement containingthe salient features of the financial statements of theSubsidiaries and Joint Venture has been provided in FormAOC-1 and is annexed as Annexure - 1 and forms a part ofthis Annual Report.
Further, the financial statement of the subsidiaries andjoint venture has been prepared and consolidated with theCompany and forms an integral part of this Report. Theconsolidated financial statements of the Company areprepared in accordance with Indian Accounting Standardsnotified under the Companies (Indian Accounting Standards)Rules, 2015 (Ind AS) and forms an integral part of this report.
The financial of its aforesaid subsidiaries are not attached tothis Report and pursuant to the provisions of Section 136 ofthe Act, the Company will make available the said financialstatements of the Subsidiaries upon a request by anymember of the Company. The members desiring the financialstatements of the Subsidiaries, may send their request inwriting to the Company at co.sec@laxmidentallimited.com.The Company has placed separately, the audited accountsof its subsidiaries on its website at www.laxmidentallimited.com in compliance with the provisions of Section 136 of theAct.
The financial statements of the Company have been preparedin accordance with the Indian Accounting Standards (“IndAS") as notified under Section 133 of the Act read with theCompanies (Accounts) Rules, 2014 and Regulation 48 of theSEBI Listing Regulations for the financial year 2024-25 asapplicable to the Company.
The estimates and judgments relating to the financialstatements are made on a prudent basis, so as to reflectin a true and fair manner, the form and substance oftransactions and reasonably present the Company's state ofaffairs, profits and cash flows for the financial year endedMarch 31, 2025.
> During 2024-25, the shareholders of the Companyat their EGM held on June 07, 2024, had approvedan increase in Authorized Share Capital of theCompany, pursuant to said approval the AuthorizedShare Capital of the Company was increased fromINR 14,46,00,000/- (Indian Rupees Fourteen Croresand Forty Six Lacs) divided into 24,60,000 (Twenty
Four Lacs Sixty Thousand) Equity Shares having facevalue of INR 10/- (Indian Rupees Ten Only) each and
3.00. 000 (Three Lacs) Preference Shares of INR 400/-(Indian Rupees Four Hundred) to INR 25,00,00,000(Indian Rupees Twenty-Five Crores Only) consisting of
1.30.00. 000 (One Crore Thirty Lacs) Equity Shares offace value of INR 10/- (Indian Rupees Ten) each and
3.00. 000 (Three Lacs) Preference Shares of face valueof INR 400/- (Indian Rupees Four Hundred) each.
> Further in accordance with the provisions of Section61(1)(d) of the Act, the shareholders passed a resolutionin its EGM held on June 07, 2024, approving the sub¬division of the Equity Shares of the Company therebyreducing the face value of each Equity Share havingface value of INR 10/- (Indian Rupees Ten) each fullypaid up in-to face value of INR 2 (Indian Rupees Two)each fully paid up.
> The shareholders of the Company, at their EGM held onJune 18, 2024, has approved:
• Change of name of the Company from LaxmiDental Export Private Limited to Laxmi DentalPrivate Limited, thereby altering name Clause ofMemorandum of Association of the Company.
• Conversion of the Company from a Private LimitedCompany in to a Public Limited Company.
> During 2024-25, the shareholders of the Company attheir EGM held on June 18, 2024, has approved:
• Adoption of new set of AOA,
• Inclusion of Investor Specific Articles in theexisting AOA
> The shareholders of the Company at their AnnualGeneral Meeting held on September 07, 2024, hasapproved amendment to AOA. By the said amendmentClause 3 of the Preamble and Article 135 of the PartA of the AOA was amended in order to align partof the AOA with the IPO plan of Company. Further,existing Part B of AOA, was replaced with new PartB in order to incorporate various amendment madein the Shareholders' Agreement and amendmentagreements(s).
Further, all articles of Part B terminated and ceasedto have any force and effect from the date of receipt ofthe final listing and trading approvals from the stockexchanges for commencement of trading of the equityshares of the Company.
The Company has Employee Stock Option Plan namelyLaxmi Dental Stock Option Scheme, 2024' (“ESOP 2024”/“Scheme”)”. The said ESOP 2024 is in compliance with theSEBI (Share Based Employee Benefits and Sweat Equity)Regulations, 2021 (hereinafter referred to as “SEBI SBEB &SE Regulations”) and have also been ratified subsequentlyby the shareholders through Postal Ballot, post listing ofshares, on May 17, 2025. The Nomination and RemunerationCommittee of the Board of Directors of the Companyinter alia, administers and monitors the ESOP 2024 of theCompany.
During the FY under review, the Nomination andRemuneration Committee of the Board of Directors, at itsmeeting held on December 13, 2024, has granted 3,51,672(Three Lacs Fifty-One Thousand Six Hundred and Seventy-Two) Employees Stock Options exercisable into not morethan 3,51,672 (Three Lacs Fifty-One Thousand Six Hundredand Seventy-Two) Equity Shares of the Company of facevalue of INR 2/- each fully paid-up, under the ESOP 2024, tothe option grantees.
The statutory disclosures as mandated under the Act andSecurities and Exchange Board of India (Share BasedEmployee Benefits and Sweat Equity), Regulations, 2021(SBEB&SE Regulation) and a certificate from SecretarialAuditors, confirming implementation of the Scheme inaccordance with SBEB&SE Regulations and Membersresolutions have been hosted on the website of the Companyat www.laxmidentallimited.com and the same will beavailable for electronic inspection by the Members duringthe Annual General Meeting (AGM) of the Company.
A statement containing the relevant disclosures pursuant toRule 12(9) of the Companies (Share Capital and Debentures)Rules, 2014, and Regulation 14 of the SEBI SBEB&SERegulations for the financial year ended on March 31, 2025can be accessed on the website of your Company at: www.laxmidentallimited.com.
During the financial year under review, the Company hasnot accepted any deposit as covered under Section 73 andSection 76 of the Act read with Companies (Acceptance ofDeposits), Rules, 2014. As on March 31, 2025 there were nodeposits lying unpaid or unclaimed.
During the financial year under review, the Company has notborrowed any amount from the Director(s) or their relative.
Further, details of unsecured loan taken in previous year(s)and outstanding as on March 31, 2025, are given in the notesto the Financial Statements, as included in this AnnualReport.
The Director(s) have confirmed that money given by them isnot being given out of funds acquired by them by borrowingor accepting loans or deposits from others and the Company.
Information related to conservation of energy, researchand development, technology absorption, foreign exchangeearnings and outgo as required under Section 134(3)(m) ofthe Act and Rule 8(3) of Companies (Accounts) Rules, 2014 isannexed herewith as Annexure - 2 and forms a part of thisAnnual Report.
The Company's philosophy on Corporate Governance aimsto attain the highest level of transparency and accountabilitytowards safeguarding and adding value to the interests ofvarious stakeholders.
The Company has been committed to maintain the higheststandards of ethics and governance, resulting in enhancedtransparency for the overall benefit of all stakeholders.The Company has implemented all the stipulations asspecified in the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 and the requirements setout by Securities Exchange Board of India.
The Company strives to undertake best CorporateGovernance practices for enhancing and meetingstakeholders' expectations while continuing to comply withthe mandatory provisions of Corporate Governance underthe applicable framework of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015.
The Company has given its deliberations to provide all theinformation in the Directors' Report and the CorporateGovernance Report as per the requirements of the CompaniesAct, 2013, SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015 and the Listing Agreemententered by the Company with the Stock Exchanges.
Pursuant to Regulation 34(3) read with Schedule V of theSEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, the applicable Regulations as issuedby SEBI and as amended from time to time a report onCorporate Governance along with a Certificate from M/s M.Jawadwala & Co., Practicing Company Secretaries, (UniqueID: S2016MH383700; Peer Review No.: 5317/2023) regarding
compliance of conditions of Corporate Governance isannexed herewith as Annexure - 3 & 4 respectively andforms a part of this Annual Report.
The certification by Chief Executive Officer and ChiefFinancial Officer as per Regulation 17(8) of SEBI (ListingObligation and Disclosure Requirements) Regulations, 2015is annexed herewith as Annexure - 5 and forms a part of thisAnnual Report.
The Board of Directors has adopted the Code of Conductand business principles for all the Board members includingExecutive/Non-Executive Directors, senior managementand all the employees of the Company for conductingbusiness in an ethical, efficient and transparent manner soas to meet its obligations to its shareholders and all otherstakeholders and the same has also been placed on theCompany's website - https://www.laxmidentallimited.com/corporate governance.
The Board Members and Senior Management have affirmedtheir compliance with the Code and pursuant to Regulation26(3) read with Schedule V of SEBI (Listing Obligations andDisclosure Requirements) Regulations 2015 a declarationsigned by the Managing Director & CEO to this effect isannexed herewith as Annexure - 10 and forms a part of thisAnnual Report.
Pursuant to Regulation 34(2)(e) read with Schedule V of SEBIListing Regulations, Management Discussion and AnalysisReport with detailed review of the operations, state of affairs,performance and outlook of the Company for the reportingyear is annexed herewith as Annexure - 6 and forms a partof this Annual Report.
Since the Company got listed on January 20, 2025, and nameof the Company has not been in the list of top 1000 listedentities based on market capitalization as on March 31,2025, Business Responsibility and Sustainability Reportingis not applicable to the Company for financial year 2024-25.
The Board of Directors of the Company is led by theChairman and comprises of 6 (Six) Directors, consisting of
1 (One) Whole-time Director 1 (One) Managing Director, 1(One) Non-Executive-Nominee Director and 3 (Three) Non¬Executive Independent Directors (including One (1) WomanIndependent Director).
The composition of Board of directors as on March 31, 2025are as follows:
Name of Director
Designation
Rajesh Vrajlal Khakhar
Chairman and Whole-timedirector
Sameer Kamlesh Merchant
Managing Director
1Sumona Chakraborty
Non-Executive, NomineeDirector
Anjana Grewal
Non-Executive, IndependentDirector
Devesh Ghanshyam Chawla
Rajesh Shashikant Dalal
1Sumona Chakraborty ceased to be nominee director w.e.f. closureof business hours of June 06, 2025.
The details of the Board and Committee Composition, tenure,cessation, appointment or re-appointment of Directors areprovided in the Corporate Governance Report as annexedherewith as Annexure - 3 and forms a part of this AnnualReport. The constitution of the Board of the Company is inaccordance with Section 149 of the Act and Regulation 17 ofthe SEBI Listing Regulations.
The following Director is proposed to be appointed at theensuing AGM, the brief details of which are mentioned in theNotice of 21st AGM forming part of this Annual Report:
Based on the recommendation of the Nomination andRemuneration Committee, the Board has appointed Dr.Anil Arora (DIN: 03469947) as an Additional Director in thecapacity of Non- Executive Non- Independent Director,subject to approval of the Members of the Company.
In accordance with the provisions of the Act, SameerKamlesh Merchant (DIN: 00679893), Managing Director,retires from the Board by rotation and being eligible andoffers himself for re-appointment. The Board recommendsthe said re-appointment at the 21st AGM. The Board ofDirectors, based on the recommendation of the Nominationand Remuneration Committee (“NRC”) has recommendedhis appointment.
Further, the brief resume and other details relating tothe Director seeking appointment or re-appointment,as stipulated under Regulation 36 of the SEBI ListingRegulations and Secretarial Standard 2 (“SS-1”), areprovided in the Notice convening the ensuing AGM.
During the financial year under review, the Non-ExecutiveDirectors of the Company had no pecuniary relationship ortransactions with the Company, other than the commission,and reimbursement of expenses, if any, incurred by them forthe purpose of attending meetings of the Board/Committeeof the Company
Based on the written representations received from theDirectors, none of the above directors are disqualified underSection 164 (2) of the Act, and are also not debarred by SEBIor any other statutory authority for holding office of a Director.The Directors have also made necessary disclosures asrequired under provisions of Section 184(1) of the Act. Asrequired by SEBI Listing Regulations, a certificate fromCompany Secretary in practice, that none of the Directors onthe Board of the Company have been debarred or disqualifiedfrom being appointed or continuing as Directors of theCompany, by SEBI, MCA or any such statutory authorities,is annexed to the Corporate Governance Report as annexedherewith as Annexure - 3 and forms a part of this AnnualReport.
In terms of Section 203 of the Act read with Companies(Appointment and Remuneration of Managerial Personnel)Rules, 2014 and Regulation 30 of SEBI Listing Regulations,the KMP's of the Company as on March 31, 2025 are:
Name of the KMP
Whole-time director
Chief Executive Officer
Dharmesh Bhupendra
Chief Financial Officer
Dattani
Nupur Joshi
Company Secretary
During the financial year under review:
> Kartik Shah has resigned from the position of CompanySecretary of the Company w.e.f. July 19, 2024.
> Nupur Joshi was appointed as the Company Secretaryand Compliance Officer of the Company w.e.f. July 20,2024.
> Dharmesh Bhupendra Dattani was appointed as theChief Financial Officer of the Company w.e.f. July 20,2024.
> Rajesh Vrajlal Khakhar (DIN: 00679903) was appointedas Chairman and Whole-time director w.e.f. August 13,2024.
> Sameer Kamlesh Merchant (DIN: 00679893) wasappointed as Managing Director & Chief ExecutiveOfficer w.e.f. August 13, 2024.
The Senior Managerial Personnel (“SMP”) of the Company
as on March 31, 2025 are:
Name of the SMP
Amrish Mahendrabhai
Vice-President, Head of
Desai
Operations, USA & India
Sarfaraz Nasir Merchant
Vice-President, Head ofOperations of the domesticdental laboratory, laboratorydivision
Arun B. John
Vice-President, Sales of thealigner division
The details of the appointment and cessation of SMP areprovided in the Corporate Governance Report as annexedherewith as Annexure - 3 and forms a part of this AnnualReport.
All members of the Board of Directors and Senior ManagementPersonnel affirmed compliance with the Company's Code ofConduct Policy for financial year 2024-25.
The Company has received disclosures/declarations fromall the Independent Directors of the Company under Section149(7) of the Act and Regulation 25(8) of the SEBI ListingRegulations and have confirmed that they fulfill the criteriaof independence as prescribed under Section 149(6) of theAct and Regulation 16(1)(b) of the SEBI Listing Regulations,and have also confirmed:
1. that they are not aware of any circumstance orsituation, which exist or may be reasonably anticipated,that could impair or impact their ability to dischargetheir duties with an objective independent judgmentand without any external influence;
2. t hat they have complied with the Code of Conduct ofIndependent Directors prescribed under Schedule IV ofthe Act; and
3. that they have duty registered their names in theIndependent Directors' Databank maintained by theIndian Institute of Corporate Affairs, in terms of Section150 of the Act read with Rule 6 of the Companies(Appointment and Qualifications of Directors)Rules, 2014 including any amendments thereto andindependent of the management of the Company.
The Company on recommendation of its Nomination andRemuneration Committee has laid down a Nomination andRemuneration Policy in compliance with Section 178(3) of theAct read with the Rules made therein and Regulation 19(4)read with Part D of Schedute II of SEBI Listing Regutationsentered with the Stock Exchanges (as amended from time totime). The Company affirms that the remuneration paid tothe Directors are as per the terms laid out in the Nominationand Remuneration Policy of the Company.
The Nomination and Remuneration Policy of the Companyfor appointment and remuneration of Directors, KeyManagerial Personnel (“KMP”) and Senior ManagementPersonnel including criteria for determining qualifications,positive attributes, independence of a Director and othermatters provided under sub-section (3) of Section 178 ofthe Companies Act, 2013 is available on the Company'swebsite at: https://www.laxmidentallimited.com/corporategovernance/policies
The details of remuneration to Directors, Key ManagerialPersonnel of the Company and other information asrequired under Section 197(12) of the Act read with Rule5(1) of the Companies (Appointment and Remuneration ofManagerial Personnel) Rules, 2014 is annexed herewith asAnnexure - 7 and forms a part of this Annual Report.Pursuant to Section 136(1) of the Act, the Directors'Report excludes the information on employees' particularsmentioned in Section 197(12) of the Companies Act, 2013read with Rule 5(2) and 5(3) of the Companies (Appointmentand Remuneration of Managerial Personnel) Rules, 2014 andCopies of the said statement are available at the registeredoffice of the Company during the designated working hoursfrom 21 days before the AGM till the date of the AGM. Anymember interested in receiving the said statement maywrite to the Company Secretary, stating their Folio No./DPID& Client ID.
Pursuant to Section 134(3)(a) and Section 92(3) of the Actread with Rule 12(1) of the Companies (Management andAdministration) Rules, 2014, a copy of the Annual Return isavailable on Company's website at: www.laxmidentallimited.com.
This Annual Return is subject to such changes/alterations/modifications as may be required to carry out subsequentto the adoption of the Directors' Report by the Shareholdersat the 21st Annual General Meeting and receipt of Certificatefrom Practicing Company Secretary (PCS) which theshareholders agree and empower the Board/Company anda copy of the final Annual Return as may be filed with theMinistry of Corporate Affairs would be furnished on thewebsite of the Company.
Pursuant to the provisions of Section 134(3) (c) and 134(5)of the Act, the Directors to the best of their knowledge andability, hereby confirm that:
a. i n preparation of the annual accounts, the applicableaccounting standards have been followed and there areno material departures;
b. we have selected such accounting policies and appliedthem consistently, and made judgments and estimatesthat are reasonable and prudent so as to give a trueand fair view of the state of affairs of the Company atthe end of the financial year and of the profit of theCompany for that period;
c. we have taken proper and sufficient care towardsthe maintenance of adequate accounting recordsin accordance with the provisions of the Act forsafeguarding the assets of the Company and forpreventing and detecting fraud and other irregularities;
d. we have prepared the annual accounts on a goingconcern basis;
e. we have laid down internal financial controls, which areadequate and are operating effectively;
f. we have devised proper systems to ensure compliancewith the provisions of all applicable laws, and suchsystems are adequate and operating effectively.
The Board of Directors met 22 (Twenty-Two) times in thefinancial year 2024-25. The intervening gap between twoconsecutive meetings was within the maximum period
mentioned under Section 173 of the Act, SecretariatStandard on Meetings of the Board “SS-1”) and SEBI ListingRegulations, as amended from time to time. The detailedinformation on the meetings of the Board is inctuded inthe Corporate Governance Report which forms part of thisAnnual Report.
Pursuant to the provisions of Section 134, 178 and ScheduleIV of the Act and the SEBI Listing Regulations, the Boardcontinues to adopt formal mechanism for evaluating its ownperformance as well as that of its Committees and individualDirectors. The exercise has been carried out through astructured evaluation process, covering various aspects ofthe functioning of the Board, such as composition of theBoard and Committees, effectiveness of Board process,information, experience and competencies, performanceof specific duties and obligations, governance issues etc.A separate exercise was carried out to on an annual basisto evaluate the performance of individual Directors on thebasis of questionnaire containing criteria such as level ofparticipation by individual Directors, independent judgementby the Director, understanding of the Company's businessetc.
The performance evaluation was carried out by theNomination and Remuneration Committee in its meetingheld on December 13, 2024. The recommendations of theCommittee were subsequently considered by the Board atits meeting held on December 13, 2024, thereby concludingthe performance evaluation process.
The evaluation of the Independent Directors was carried outby the entire Board excluding the Director being evaluatedand that of the Non-Independent Directors were carried outby the Independent Directors in their separate meeting heldon January 07, 2025.
The outcome of the performance evaluation as carried outon the basis of the above mechanism was discussed by theNomination and Remuneration Committee and the Boardat their respective meetings and noted the performance tobe satisfactory and it also reflected the commitment of theBoard members and its Committees to the Company.
As stipulated by the Code of Independent Directors underSchedule IV of the Act and Regulation 25(3) of SEBI ListingRegulations, a separate meeting of the IndependentDirectors of the Company was held on January 07, 2025.
During the financial year under review, there were no changein the composition of the Committees of the Board. As on thedate of this Report, the following are the Committees of theBoard:
a. Audit Committee
b. domination and Remuneration Committee
c. Stakeholders' Relationship Committee
d. Corporate Social Responsibility Committee
e. Initial Public Offer (“IPO”) Committee
f. Committee of Independent Directors in connection withInitial Public Offering (“IPO”)
Note: 'After the end of the financial year and before the signing ofthis report the Nomination and Remuneration Committee was re¬constituted. The details of such re-constitution was given in theCorporate Governance Report.
The composition of various Committees and meetings heldis detailed below:
The Board has constituted Audit Committee inaccordance with the provisions of Section 177 of theAct and Regulation 18 of SEBI Listing Regulations.The Audit Committee met 8 (Eight) times during thefinancial year 2024-2025. The Company Secretary ofthe Company acts as a Secretary to the Committee.
The details of the Committee along with their charters,composition and meetings held during the financialyear are given in the Corporate Governance Report asannexed herewith as Annexure - 3 and forms a part ofthis Annual Report.
During the year under review, the Board has acceptedall recommendations of the Audit Committee andaccordingly no disclosure is required to be made inrespect of non-acceptance of any recommendation ofthe Audit Committee by the Board.
The Board has constituted a Nomination andRemuneration Committee in accordance with theprovisions of Section 178 of the Act and Regulation19 of SEBI Listing Regulations. The Nominationand Remuneration Committee met 4 (Four) timesduring the financial year 2024-2025. During the year,all recommendations made by the Committee wereapproved by the Board.
The details of the Committee along with their charters,composition and meetings held during the year aregiven in the Corporate Governance Report as annexedherewith as Annexure - 3 and forms a part of thisAnnual Report.
The Board had constituted a Stakeholders' RelationshipCommittee as per the provisions of Section 178(5) ofthe Act and Regulation 20 of SEBI Listing Regulations.The Stakeholders' Relationship Committee met 1 (One)time during 2024-2025.
The Board has duly constituted Corporate SocialResponsibility (“CSR”) Committee. Further, Section 135of the Act and rules made thereunder are not applicableto the Company 2024-25, therefore the Company wasnot required to undertake CSR activities and spendamount toward CSR activities.
During the financial year under review, no meeting ofthe CSR Committee was held.
The details of the Committee along with their chartersand composition are given in the Corporate GovernanceReport as annexed herewith as Annexure - 3 and formsa part of this Annual Report.
As the Company came up with the Initial Public Offering(IPO), the Board has constituted a IPO Committee tooversee the execution of the Company's IPO process.During financial year 2024-25, 2(Two) meetings as onSeptember 12, 2024 and January 10, 2025 of the IPOCommittee were held.
The composition and other details of the Committeeare given in the Corporate Governance Report asannexure herewith as Annexure - 3 and forms a part ofthis Annual report.
The equity shares of the Company got listed on theStock Exchanges on January 20, 2025, the purpose ofthe IPO Committee was duly achieved and accordinglythe committee was dissolved by the Board of Directorsin their meeting held on February 13, 2025.
Pursuant to the requirement of SEBI (Issue of Capitaland Disclosure Requirements) Regulations, 2018,the Board constituted the Committee of IndependentDirectors to provide a recommendation in the priceband in connection with the Offer in the IPO.
The composition and other details of the Committeeare given in the Corporate Governance Report asAnnexure - 3 and forms a part of this Annual report.
M/s M S K A & Associates, Chartered Accountants(Firm's Registration No.: 105047W), the StatutoryAuditors of the Company were re-appointed at the20th Annual General Meeting (AGM) of the Companyheld on September 07, 2024, for the term of 5 (Five)consecutive years from the conclusion of 20th AGM tillthe conclusion of 25th AGM of the Company at suchremuneration as shall be fixed by the Board of Directorsof the Company from time to time in consultation withStatutory Auditors.
Pursuant to Section 139 and 141 of the Act and relevantRules prescribed thereunder, the Statutory Auditorshave confirmed that they are not disqualified fromcontinuing as Statutory Auditors of the Company. Therewere no qualifications, reservations, adverse remarksor disclaimers made by the Statutory Auditor in theirReport. The Notes to the Financial Statements referredin the Auditor's Report are self-explanatory andtherefore do not call for any comments under Section134 of the Act, The Auditor's Report is enclosed with theFinancial Statements in this Annual Report.
The provisions of Section 148 of the Act read with theCompanies (Cost Records and Audit) Rules, 2014,related to maintenance of cost audit records andfiling the same is not applicable to the Company, thusappointment of Cost Auditor is not applicable for thefinancial year 2024-25.
Pursuant to the provisions of Section 204 of the Act readwith the Companies (Appointment and Remunerationof Managerial Personnel) Rules, 2014 and Regulation24A of SEBI Listing Regulations, M/s. M Jawadwala& Co, Peer Reviewed Firm of Practicing Company
Secretaries, (Membership No.: - A30840/C.P. No.: -16191) (Peer Review: - 5317/2023) were appointed asthe Secretarial Auditors of the Company to conductthe secretarial audit of the Company for financialyear 2024-2025. The Secretarial Audit Report, in theprescribed Form No. MR-3 received from SecretarialAuditors for the financial year ended March 31, 2025,is annexed to this Report as Annexure 8 and formspart of this Annual Report. There is no qualification,reservation, adverse remark, or disclaimer given by theSecretarial Auditors in their Reports.
As on March 31,2025, the Company has 2 (two) materialsubsidiary(ies) viz. Bizdent Devices Private Limited(Indian Company) and Laxmi Dental Lab USA Inc.(Foreign Company). Therefore, as per the requirementof Regulation 24A of SEBI Listing Regulations, theSecretarial Audit Report of the Material Unlisted IndianSubsidiary of the Company for the financial year endedMarch 31, 2025 as received from M/s. M. Jawadwala& Co., Practicing Company Secretaries, is annexed asAnnexure - 9 and forms part of this report.
The Company has undertaken an Annual SecretarialCompliance Audit for 2024-25 pursuant to Regulation24A (2) of the SEBI Listing Regulations. The AnnualSecretarial Compliance Report for the financial yearended March 31, 2025 has been submitted to the StockExchanges on May 30, 2025 and the said report may beaccessed on the Company's website at the link www.laxmidentaUimited.com.
Further, pursuant to SEBI (Listing Obligations andDisclosure Requirements) (Third Amendment)Regulations, 2024 dated December 12, 2024, the Boardof Directors have approved and recommended to theshareholders the appointment of M/s. M Jawadwala& Co, Peer Reviewed Firm of Practicing CompanySecretaries, (Membership No.: - A30840/C.P. No.: -16191) (Peer Review: - 5317/2023) as the SecretarialAuditors of the Company for a term of 5 (Five)consecutive years commencing from 2025-26 to 2029¬30. The resolution seeking approval of shareholders forthe same is set out in the Notice calling the 21st AnnualGeneral Meeting of the Company.
M/s. M Jawadwala & Co, have consented to the saidappointment and confirmed that their appointment, ifmade, would be within the limits specified in the Act &Rules made thereunder and SEBI Listing Regulations,2015 and as given in SEBI Circular No.: SEBI/ HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31,2024. They have further confirmed that they are notdisqualified to be appointed as Secretarial Auditors
in terms of disqualifications in terms of provisions ofthe Act & Rules made thereunder and SEBI ListingRegulations.
Pursuant to the provisions of Section 138 of the Actand read with Companies (Accounts) Rules, 2014, M/s.Bathiya & Associates LLP, Chartered Accountants(FRN.101046W/W100063) were appointed as theInternal Auditors to conduct the internal audit of theCompany for 2024-25. The Audit Committee considersand reviews the Internal Audit Report submitted by theInternal Auditors on a quarterly basis.
For 2024-2025, the provisions of Cost Audit as specified bythe Central Government under Section 148 of the Act readwith the Rules framed thereunder were not applicableto the Company. As per Section 148 of the Act read withthe Companies (Cost Records and Audit) Rules, 2014 theCompany was not required to maintain cost records for thefinancial year 2024-2025.
Pursuant to Section 143(12) of the Act, during the financialyear under review there were no frauds reported by theStatutory Auditors, Internal Auditors, Cost Auditors andSecretarial Auditors of the Company to the Audit Committeeor the Board of Director. Hence, there is nothing to reportunder Section 134(3)(ca) of the Act.
The Company has in place adequate Internal FinancialControls system as required under Section 134(5)(e) ofthe Act. The system covers all major processes includingoperations to ensure reliability of financial reporting,compliance with policies, procedures, laws and regulations,safeguarding of assets and economical and efficient useof resources. During the financial year under review, suchcontrols were tested with reference to financial statementsand no reportable material weakness in the formulation oroperations were observed.
The Statutory Auditors and the Internal Auditors are, interalia, invited to attend the Audit Committee Meetings andpresent their observations on adequacy of Internal FinancialControls and provide suggestive measures to resolvedifferences and close the gaps. Accordingly the AuditCommittee makes observations and recommends to theBoard of Directors.
During the financial year under review, no material orserious observation has been received from the Auditorsof the Company citing inefficiency or inadequacy of suchcontrols. An extensive internal audit was carried out byInternal Auditors and post audit reviews were also carriedout to ensure follow up on the observations made.
PARTICULARS OF LOANS, GUARANTEES ANDINVESTMENTS:
During the financial year under review, the Company hasbeen investing and deploying its surplus funds in securitieswhich were within the overall limit of the amount and withinthe powers of the Board as applicable to the Company interms of Section 134(3)(g), 179 and 186 of the Act.
The Company makes investments or extends loans to itssubsidiaries for their business purpose. The particulars ofall such loans, guarantees and investments are entered intothe register maintained by the Company for the purpose andare appended in notes to the financial statements.
PARTICULARS OF CONTRACT OR ARRANGEMENTS WITHRELATED PARTIES:
The Company has formulated a Policy on related partytransactions in accordance with the provisions of Sections177 and 188 of the Act, and Rules made thereunder readwith Regulation 23 of SEBI Listing Regulations and the sameis available on the website of the Company at https://www.laxmidentallimited.com/public/investors/policies/Related-Party-Transaction-Policy.pdf. The Policy intends to ensurethat proper reporting, approval and disclosure processesare in place for all transactions between the Company andits related parties.
None of the contract or arrangement or transaction with anyof the related parties were in conflict with the interest of theCompany. There were no material related party transactionsby the Company during the financial year under review.Since all the transactions with related parties during theyear were on arm's length basis and in the ordinary course ofbusiness, hence, the disclosure of related party transactionsas required under Section 134(3)(h) of the Act in Form AOC-2is not applicable to the Company for 2024-25.
Details of related party transactions entered into by theCompany, in terms of Ind AS-24 have been disclosed inthe notes to the accounts in the financial statement (bothstandalone and consolidated), forming part of this AnnualReport.
Prior omnibus approval of the Audit Committee is obtainedon an annual basis for transaction with related partiesconsidering repetitiveness of the transactions (in past or in
future); justification for the need of omnibus approval andtransaction made on arm's length basis i.e. at market price.The transactions entered pursuant to the omnibus approvalso granted and a statement giving details of all transactionswith related parties are placed before the Audit Committeefor their review on a periodic basis.
MATERIAL CHANGES AND COMMITMENTS, IF ANY,AFFECTING THE FINANCIAL POSITION OF THE COMPANYTHAT OCCURRED BETWEEN THE END OF THE FINANCIALYEAR TO WHICH THE FINANCIAL STATEMENTS RELATEAND THE DATE OF THE REPORT:
There are no material changes and commitments affectingthe financial position of the Company which had occurredbetween the end of the financial year and the date of thisAnnual Report.
RISK MANAGEMENT:
The Board of Directors of your Company have identifiedindustry specific risk and other external, internal, politicaland technological risk which in opinion of the board are threatto the Company and Board has taken adequate measuresand actions which are required to take for diminishing theadverse effect of the risk.
The Risk Management Policy of the Company is availableon the website and can be accessed at: https://www.laxmidentallimited.com/corporate governance/policies
VIGIL MECHANISM:
Pursuant to Section 177 (9) of the Act and Regulation 22of SEBI Listing Regulations, the Company has establisheda Vigil Mechanism for Directors and employees to reportgenuine concerns to the management, instances ofunethical behaviour, actual or suspected, fraud or violationof the Company's code of conduct or ethics policy. ThisPolicy enables the employees or other connected personhaving interest in any transactions with the Company toreport any unethical or improper practices noticed in theorganization. The Company strongly follows the conduct ofits affairs in a fair and transparent manner by adoption ofhighest standards of professionalism, honesty integrity andethical behaviour and accordingly as per the requirementof the Act and the SEBI Listing Regulations, the Companyha s framed its Vigil Mecha nism Policy to enable a ll theemployees and the Directors to report any violation of theCode of Ethics as stipulated in the said policy. The policy alsoprovides access to the Chairperson of the Audit Committeeunder certain circumstances. The Company is committedto adhere to highest possible standards of ethical, moraland legal business conduct, to open communication and to
provide necessary safeguards for protection of Directors oremployees or any other person who avails the mechanismfrom reprisals or victimization, for whistle blowing in goodfaith.
Details of establishment of the Vigil Mechanism Policyis available on the Company's website at https://www.laxmidentallimited.com/corporate governance/policies andalso set out in the Corporate Governance Report as annexedherewith as Annexure - 3 and forms a part of this Report.
The Company has constituted Corporate Social Responsibility(“CSR") Committee in compliance with the provisions ofSection 135 of the Act read with the Companies (CorporateSocial Responsibility Policy) Rules, 2014. At present, the CSRCommittee of the Board consists of Rajesh Vrajlal Khakhar(Chairman and Whole-time director), Sameer KamleshMerchant (Managing Director & CEO) and Anjana Grewal(Independent Director) as the Members.
Further, Section 135 of the Act and rules made thereunderare not applicable to the Company for the financial year 2024¬25, therefore the Company was not required to undertakeCSR activities and spend amount toward CSR activities.
The CSR policy formulated by the Company is available on theCompany's website: https://www.laxmidentallimited.com/public/investors/policies/Corporate-Social-Responsibility-Policy.pdf
The Company has been committed to create and provide anenvironment that is free from any kind of discrimination andharassment including sexual harassment. The Company hasformulated and adopted an anti-sexual harassment policy inline with requirements of The Sexual Harassment of Womenat Workplace (Prevention, Prohibition and Redressal) Act,2013 ('PoSH') and Rules made thereunder provides amechanism for the resolution, settlements or prosecutionof acts or instances of sexual harassment at workplace andensures that all employees are treated with respect anddignity. The POSH Policy is also placed on the Company'swebsite - https://www.laxmidentallimited.com/public/investors/policies/Prevention-of-Sexual-Harassement-Policy.pdf
All women associates (permanent, temporary contractualand trainees) as well as any women visiting the Company'soffice premises or women service providers are coveredunder this Policy. During the financial year under review,
no complaints with allegations of sexual harassment werereceived by the Company.
The Company has complied with provisions relating to theconstitution of Internal Complaints Committee (“ICC") in linewith the requirements of the Sexual Harassment of Womenat Workplace (Prevention, Prohibition and Redressal) Act,2013.
The necessary disclosure in terms of requirements of Rule8 of the Companies (Accounts) Rules, 2014 and SEBI ListingRegulations in this regard is given below:
Sr.
No. of
Complaints
1.
Number of complaints of sexualharassment received in the year
Nil
2.
Number of complaints disposed ofduring the year
3.
Number of cases pending for morethan ninety days
In terms of Regulation 44 of SEBI Listing Regulations andin compliance with the provisions of Section 108 of the Actread with Rule 20 and other applicable provisions of theCompanies (Management and Administration) Rules, 2014(as amended), the items of business specified in the Noticeconvening the 21st AGM of the Company shall be transactedthrough electronic voting system only and for this purpose theCompany is providing e-Voting facility to its' Members whosenames will appear in the register of members as on the cut¬off date (fixed for the purpose), for exercising their right tovote by electronic means through the e-voting platform tobe provided by MUFG Intime India Private Limited (formerlynamed as Link Intime India Private Limited). The detailedprocess and guidelines for e-Voting have been provided inthe notice convening the meeting.
The Company has developed and maintained its fullyfunctional website www.laxmidentallimited.com which hasbeen designed to exhibit the detailed information on theCompany's business. The site carries a comprehensivedatabase of information of the Company from investor'sperspective too. All the mandatory information anddisclosures as per the requirements of the CompaniesAct, 2013, Regulation 46 of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015 and alsothe non-mandatory information of investors' interest /knowledge has been duly provided on the website of theCompany.
The Company has amended the Code of Conduct forProhibition of Insider Trading (“the Code") effectiveFebruary 13, 2025 in accordance with the requirements ofSEBI (Prohibition of Insider Trading) Regulations, 2015, asamended from time to time and is available on our website,at https://www.laxmidentaUimited.com/public/investors/
policies/Code-of-Conduct-for-Insider-Trading.pdf.
Pursuant to the internal code of conduct for preventionof insider trading as framed by the Company under SEBI(Prohibition of Insider Trading) Regulations, 2015 (asamended from time to time), the trading window closure(s)are intimated in advance to all the designated person andduring the period, Directors, KMPs, employees, designatedperson, their relatives and other connected persons of theCompany are not permitted to trade in the securities of theCompany.
The Company is maintaining a Structured Digital Databaseas required under regulation 3(5) of SEBI (Prohibition ofInsider Trading) Regulations, 2015. After listing, internaltrainings and awareness programmers were conductedto make the employees familiar with Code of Conduct forInsider Trading and UPSI Policy of the Company.
The Company has well defined risk managementframework in place comprising of regular audits andchecks for identifying, assessing, mitigating, monitoringand reporting risks associated with the business of theCompany. Major risks as identified are systematicallyaddressed by the concerned process owners throughrisk mitigation actions on a continuous basis.
As per Regulation 32(1) of SEBI Listing Regulations,there are no material deviations/variances noted in theCompany. The funds received pursuant to IPO, havebeen utilized for the objects stated in the prospectus.
The details of utilization of issue proceeds of the IPOis submitted to the Stock Exchanges and are availableon their websites. As on March 31, 2025, there wasno material variation between projected utilization offunds in the Offer document and the actual utilizationof funds.
The following table sets forth details of the utilization of the Net Proceeds:
Object for utilization of Net Proceeds
Total estimated amount/expenditure to be fundedfrom the Net Proceeds of IPO(In Million)
Fund utilized as onMarch 31,2025(In Million)
Repayment/prepayment, in full or in part, of certain outstandingborrowings availed by our Company
229.84
Investment in certain Subsidiaries for the repayment/prepayment, in full or in part, of certain outstanding borrowings
46.00
Funding the capital expenditure requirements for purchase ofnew machinery for our Company
435.07
7.43
Investment in our Subsidiary, Bizdent Devices Private Limited,for the capital expenditure requirements for the purchase of newmachinery
250.04
General corporate purposes
320.75
94.10
I n accordance with the requirements of SEBI (ICDR) Regulations, 2018 the Company has appointed ICRA Limited asMonitoring Agency for review and certification of utilization of the IPO proceeds to the Company.
SECRETARIAL STANDARDS:
The Company follows the applicable Secretarial Standards,issued by the Institute of Company Secretaries of India(“ICSI”) and approved by the Central Government underSection 118(10) of the Companies Act, 2013, for conveningand conducting the meeting of the Board of Director,General Meetings and other matters related thereto andhave devised proper systems to ensure the compliance ofapplicable Standards.
INDUSTRIAL RELATIONS:
The industrial relation during the financial year 2024-25 hadbeen cordial. The Directors take on record the committedsupport received from its agents, dealers, suppliers andcrucial efforts made by the senior management personnel,officers, employees and workers towards overall growth anddevelopment of the Company.
Further, the Company has a strong people policy aimed atrecruiting the best talent, training the people, engaging withthem continuously, and ensuring strong retention, thereby,laying foundation to a robust human capital. This alignmentmakes it easier for the Company and its people to worktogether toward common goals.
THE DETAILS OF APPLICATION MADE OR ANYPROCEEDING PENDING UNDER THE INSOLVENCY ANDBANKRUPTCY CODE, 2016 (31 OF 2016) DURING THEYEAR ALONG WITH THEIR STATUS AS AT THE END OFTHE FINANCIAL YEAR:
During the financial year under review, no application wasmade by the Company under the Insolvency and BankruptcyCode, 2016 neither any proceeding pending before thetribunal or any other authorities under the said Code.
DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OFVALUATION AT THE TIME OF ONE-TIME SETTLEMENTAND THE VALUATION DONE AT THE TIME OF TAKING ALOAN FROM THE BANKS OR FINANCIAL INSTITUTIONSALONG WITH THE REASONS THEREOF:
There was no instance of one-time settlement with any bankor financial institution. The Company was not required toobtain this valuation report.
SIGNIFICANT AND MATERIAL ORDERS PASSED BY THEREGULATORS OR COURTS OR TRIBUNALS IMPACTINGTHE GOING CONCERN STATUS AND COMPANY'SOPERATIONS IN FUTURE:
There has been no significant material order passed byregulators or courts or tribunals impacting going concernstatus and Company's operations in future.
COMPLIANCE OF THE PROVISIONS RELATED TO THEMATERNITY BENEFIT ACT, 1961:
The Company is committed to provide safe, supportive anddignified working environment to the women employees andhas in place policy related to Maternity Benefits which is incompliance with provisions relating to the Maternity BenefitAct, 1961. The Company has made adequate provisions toensures that maternity leave, medical benefits, and otherrelated entitlements are received by the eligible femaleemployees. Further, during the financial year under reviewthe Company is in compliance with all the applicableprovisions of Maternity Benefit Act, 1961.
GREEN INITIATIVES:
In commitment to keep in line with the Green Initiativesand going beyond it, electronic copy of the Notice of the 21stAGM of the Company including the Annual Report for thefinancial year 2024-25 are being sent to all shareholderswhose e-mail addresses are registered with the Company/Depository Participant(s).
GENERAL DISCLOSURES:
During the financial year under review, the Board of Directorsconfirm that no disclosure or reporting is necessary for thefollowing, as there were no transactions/events of suchnature:
a) there was no revision of financial statements andBoard's Report of the Company.
b) the Company has not failed to implement any corporateaction.
c) t here were no agreements entered by the Companywhich comes within the purview of Regulation 30A ofListing Regulations.
d) the trading of securities of the Company were notsuspended by the stock exchange.
e) issue of equity shares with differential rights as todividend, voting or otherwise
f) issue of shares (including sweat equity shares) toemployees of the Company under any scheme.
g) buy back of the shares of the Company.
The Directors would like to express their earnestappreciation for the assistance and co-operation receivedby the Company from its various stakeholders, financialinstitutions, banks, government authorities, vendors,customers and business associates and also acknowledgewith gratitude the encouragement and support extended byall. The Directors wish to place on record their deep sense ofappreciation to all the employees at different levels for theircontinued dedication, hard work, and contribution during thefinancial year.
Whole-time Director Managing Director
DIN:00679903 DIN:00679893
Date: August 29, 2025Place: Mumbai